24 Dec 2021 07:00
Sensyne Health and RwHealth announce a strategic partnership for SENSIGHT
Sensyne's real-world data analytics platform
Oxford, UK - December 24 2021 Sensyne Health plc (LSE:SENS or "the Company") today announces a strategic partnership with RwHealth for "SENSIGHT" Sensyne's real world data analytics platform. The agreement includes subscriptions for ten SENSIGHT seats initially. As part of this agreement, RwHealth will also become a "SENSIGHT Channel Partner" with the right to offer SENSIGHT to its customers.
London headquartered RwHealth, is a healthcare and life sciences data company providing healthcare analytics and information services to UK and international health systems. By deploying advanced Artificial Intelligence and Machine Learning technology, RwHealth is able to leverage information at a local, national and global level to create real-time and predictive analytics for healthcare and life sciences.
Lord (Paul) Drayson PhD FREng, Founder and Chief Executive Officer of Sensyne,
commented:
"RwHealth is a long-standing and trusted partner across UK and international health systems. We are excited to be working with RwHealth, both as a customer and channel partner for our SENSIGHT real world data analytics platform."
Orlando Agrippa, CEO and founder of RwHealth added:
"Sensyne has made a significant investment in clinical research and Real-World Data (RWD) provision with millions of de-identified patient data from the NHS and US. We see this as a great opportunity to enhance our offering to pharmaceutical partners in the clinical research space through the RwHealth and SENSIGHT platforms."
SENSIGHT is a clinical AI platform that provides industrial scale access to insights from anonymised and de-identified RWD, across multiple therapy areas, from Sensyne's partner healthcare organisations in the UK and US, combined with built-in simple to use research algorithms. The platform provides life science professionals, medical research academics and clinicians with instant access to AI research capability to analyse health insights to inform decision making, generate deeper insights into patient journeys and improve the speed and outcomes of clinical trials.
Notes for editors:
About Sensyne Health: https://www.sensynehealth.com/
Sensyne Health plc (LSE: SENS) is a clinical artificial intelligence company operating a unique business model - a for-profit plc making a positive social impact, sharing the financial returns it makes with health systems. The company applies clinical AI in the healthcare and life science industries. In healthcare, Sensyne delivers remote patient monitoring and real-time decision-making systems for healthcare organisations and their patients. In life sciences, Sensyne analyses large complex anonymized data sets to help life sciences companies accelerate the development of new medicines.
Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).
Contact details:
Sensyne Health |
|
| |
Lord (Paul) Drayson PhD FREng, Chief Executive Officer Dr Richard Pye, Chief Financial Officer | +44 (0) 330 058 1845 |
| |
Peel Hunt LLP (Nominated Adviser and Joint Broker) | + 44 (0) 20 7418 8900 |
| |
Dr Christopher Golden James Steel
|
|
| |
Liberum (Joint Broker) |
| ||
Bidhi Bhoma William Hall | + 44 (0) 20 3100 2000 | ||
Consilium Strategic Communications |
| ||
Mary-Jane Elliott Jessica Hodgson CSCSensynehealth@consilium-comms.com | +44 (0) 7780 600290 | ||
SternIR |
| ||
Julie Seidel Julie.seidel@sternir.com | +1 (212) 362 1200 | ||